Carter to lead Fusion Energy Division at Oak Ridge National Laboratory
In a long career full of scientific accomplishments, Brian Davison counts among his many successes the formation of ORNL’s LGBTQIA+ employee group and helping gay and lesbian staff at the lab
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.
Scientists at ORNL have discovered a single gene that simultaneously boosts plant growth and tolerance for stresses such as drought and salt, all while tackling the root cause of climate change by enabling plants to pull more carbon dioxide from the atmosphere.
Oak Ridge National Laboratory expertise in fission and fusion has come together to form a new collaboration, the Fusion Energy Reactor Models Integrator, or FERMI
Belinda Akpa is a chemical engineer with a talent for tackling big challenges and fostering inclusivity and diversity in the next generation of scientists.
From Denmark to Japan, the UK, France, and Sweden, physicist Ken Andersen has worked at neutron sources around the world. With significant contributions to neutron scattering and the scientific community, he’s now serving in his most important role yet.
Toward the goal of bringing the next generation of nuclear power reactor technology online this decade, ORNL and Analysis and Measurement Services Corporation have successfully completed loop testing of instrument and control sensors for an advanced reactor design for small modular reactors.
Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.
When COVID-19 was declared a pandemic in March 2020, Oak Ridge National Laboratory’s Parans Paranthaman suddenly found himself working from home like millions of others.
The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.